MAY2016-07-01 "Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis (FAP)"

  • Are you or do you have...?
    • 18 to 69 years of age?
    • Diagnosed Familial Adenomatous Polyposis (FAP), either clinical or genetic?
    • No previous treatment with erlotinib?
    • Otherwise healthy?
  • You may be eligible for a clinical trial opening soon that will test a weekly dose of erlotinib to see if it's safe and to see if it will reduce the number of polyps in the small intesting.
    • Enrolling sites in Rochester, MN; Salt Lake City, UT; Ann Arbor, MI; Cleveland, OH; San Juan, PR; Houston,TX; and Pittsburgh, PA
    • The study involves 6 study visits, blood and urine tests, 2 exams of your gastrointestinal (GI) system, and questionnaires about your side effects, symptoms, and experiences on the study
    • You will be on the study for about 6 months plus a follow-up phone call.
    • You will take the study drug, erlotinib, once a week for about 6 months.
    • You won't be paid, but you may receive funds to help with the expenses associated with participating in the study
    • If you choose to participate, there may be risks associated with the GI exams and blood collection procedures, and there may be side effects associated with the study drug.
    • There may or may not be a direct benefit for you. We do not know if erlotinib will be tolerable or if it will reduce the number of polyps.
  • If you are interested, email the Cancer Prevention Network Operations Office, or call 507-284-1602